
Isomorphic Labs to collaborate with Eli Lilly
Betsy Goodfellow | January 11, 2024 | News story | Research and Development | AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery
Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the company’s first pharmaceutical partnership.
Under terms of the agreement, the two companies will partner to discover small molecule therapeutics against various targets, with Isomorphic Labs receiving an upfront cash payment of $45m, as well as up to $1.7bn in performance based milestone payments. The company will also be eligible to receive subsequent tiered royalties of up to low double digits on net sales of any resulting products.
The company will utilise its next generation of AlphaFold, its updated platform which can “generate predictions for nearly all molecules in the Protein Data Bank (PDB), frequently reaching atomic accuracy,” according to the company’s website. The platform will be used to “better understand the underlying biological mechanisms of drug targets, and rationally design novel therapeutics.”
Demis Hassabis, chief executive officer and founder of Isomorphic Labs, commented: “We’re thrilled to embark on this partnership and apply our proprietary technology platform, the next generation of AlphaFold, and access to massive computing power to Lilly’s development programmes. The focus we share on advancing groundbreaking drug design approaches and appreciation of state-of-the-art science makes this partnership particularly compelling.”
Betsy Goodfellow
Related Content

AI: an early warning system for patient safety
By Sanjeev Sachdeva Safeguarding patient health is the foremost responsibility of the pharmaceutical sector. While …

Charity commits £800,000 to AI research into late breast cancer recurrence
Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

Aiforia deal to expand access to pathology AI
Aiforia has signed a commercial agreement with PathAI to make its artificial intelligence (AI) solutions …





